Lymphoma Trial, Recruiting NCT06946407 Sponsor: FengYan Jin Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT06946407
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 60 years or younger, of any sex
  • People who have been diagnosed with diffuse large B-cell lymphoma (a specific type of blood cancer) confirmed through tissue and laboratory testing, and who have not yet received any treatment for it
  • People whose cancer is limited to the central nervous system (the brain and spinal cord), with no signs of it spreading to other parts of the body, based on physical examination, imaging, and blood tests
  • People whose diagnosis meets the specific criteria for Primary Central Nervous System Lymphoma (a lymphoma that starts in the brain or spinal cord)
  • People who have provided written consent to take part, or whose legal guardian has done so on their behalf
  • People who are willing to participate in the study voluntarily

Who may not be able to join:

  • People who have another active cancer diagnosis at the same time
  • People with a known history of HIV infection or AIDS
  • People with a known allergy to any of the study drugs or their ingredients
  • People with serious other health conditions, significant abnormal laboratory results, or difficult personal or family circumstances that, in the opinion of the treating doctor, could affect safety or the ability to complete the study (confirm with trial site for details)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
FengYan Jin
Registry
ClinicalTrials.gov
Start date
2 December 2022
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov